BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Romeo AC, Ventimiglia M, Dipasquale V, Orlando A, Citrano M, Pellegrino S, Accomando S, Cottone M, Romano C. Effectiveness and safety of biologics in pediatric inflammatory bowel disease: Real-life data from the Sicilian Network. Clinics and Research in Hepatology and Gastroenterology 2020;44:223-9. [DOI: 10.1016/j.clinre.2019.05.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Dipasquale V, Lo Presti G, Romano C. Disease phenotype and outcomes of very early-onset inflammatory bowel disease. European Journal of Internal Medicine 2022. [DOI: 10.1016/j.ejim.2022.05.001] [Reference Citation Analysis]
2 Ashton JJ, Green Z, Kolimarala V, Beattie RM. Inflammatory bowel disease: long-term therapeutic challenges. Expert Rev Gastroenterol Hepatol 2019;13:1049-63. [PMID: 31657969 DOI: 10.1080/17474124.2019.1685872] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Yang M, Liu W, Deng Q, Liang Z, Wang Q. The incidence of psoriasis among smokers and/or former smokers inflammatory bowel diseases patients treated with tumor necrosis factor antagonist: A systematic review and meta-analysis. Medicine (Baltimore) 2021;100:e27510. [PMID: 34678884 DOI: 10.1097/MD.0000000000027510] [Reference Citation Analysis]
4 D'Arcangelo G, Distante M, Raso T, Rossetti D, Catassi G, Aloi M. Safety of Biological Therapy in Children With Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr 2021;72:736-41. [PMID: 33416268 DOI: 10.1097/MPG.0000000000003044] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Dipasquale V, Romano C. Genes vs environment in inflammatory bowel disease: an update. Expert Rev Clin Immunol 2022. [PMID: 35912838 DOI: 10.1080/1744666X.2022.2108407] [Reference Citation Analysis]